Methadone maintenance and HIV prevention: a cost-effectiveness analysis

Management Science

Volumn 46, Issue 8, 2000, Pages 1013-1031

  Zaric, Gregory S ^a   Brandeau, Margaret L ^a   Barnett, Paul G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; DISEASES; DRUG PRODUCTS; HEALTH CARE; MATHEMATICAL MODELS; PATIENT TREATMENT; PUBLIC POLICY; SENSITIVITY ANALYSIS; VIRUSES;

HEROIN ADDICTION; HIV PREVENTION; INJECTION DRUG USERS; METHADONE MAINTENANCE;

COST EFFECTIVENESS;

EID: 0034245527     PISSN: 00251909     EISSN: None     Source Type: Journal    
DOI: 10.1287/mnsc.46.8.1013.12025     Document Type: Article

References (74)

1. Barnett, P. G. 1999. The cost effectiveness of methadone maintenance as a health care intervention. Addiction 94 479-488.
2. _, J. H. Rodgers. 1998. The cost of substance abuse treatment: A multivariate cost function using the NDATUS. Center for Health Care Evaluation, VA Palo Alto Health Care System, Palo Alto, CA.
3. Bayoumi, A. M., D. Redelmeier. 1999. Economic methods for measuring quality of life associated with HIV infection: Do different methods give consistent results? Division of Medical Informatics, Department of Medicine, Stanford University, Stanford, CA.
4. Bellis, D. J. 1993. Reduction of AIDS risk among 41 heroin addicted female street prostitutes: Effects of free methadone maintenance. J. Addiction Disorders 12 7-23.
5. Blower, S. M., D. Hartel, H. Dowlatabadi, R. M. Anderson, R. M. May. 1991. Drugs, sex and HIV: A mathematical model for New York City. Phil. Trans. Roy. Soc. London 321 171-187.
6. Booth, R. E., T. J. Crowley, Y. Zhang. 1996. Substance abuse treatment entry, retention and effectiveness: Out-of-treatment opiate injection drug users. Drug Alcohol Depend. 42 11-20.
7. Brandeau, M. L., D. K. Owens, C. H. Sox, R. M. Wachter. 1992. Screening women of childbearing age for human immunodeficiency virus: A cost-benefit analysis. Arch. Intern. Medicine 152 2229-2237.
8. _, _, _, _. 1993. Screening women of childbearing age for human immunodeficiency virus: A model-based policy analysis. Management Sci. 39 72-92.
9. Bux, D. A., R. J. Lamb, M. Y. Iguchi. 1995. Cocaine use and HIV risk behavior in methadone maintenance patients. Drug Alcohol Depend. 37 29-35.
10. California Department of Health Services Office on AIDS. 1997. California HIV/AIDS Update 10 14.
11. Caplehorn, J. R., M. W. Ross. 1995. Methadone maintenance and the likelihood of risky needle-sharing. Internat. J. Addiction 30 685-698.
12. Caulkins, J. P., E. H. Kaplan, P. Lurie, T. O'Connor, S. H. Ahn. 1998. Can difficult-to-reuse syringes reduce the spread of HIV among injection drug users? Interfaces 28 23-33.
13. Centers for Disease Control and Prevention (CDC). 1993. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings and technical guidance on HIV counseling. Morbidity and Mortality Weekly Rep. 42 1-6.
14. _. 1998. HIV/AIDS Surveillance Report 10 1-40.
15. Chaisson, R. E., P. Bacchetti, D. Osmond, B. Brodie, M. A. Sande, A. R. Moss. 1989. Cocaine use and HIV infection in intravenous drug users in San Francisco. J. Amer. Medical Assoc. 261 561-565.
16. Contoreggi, C., V. E. Rexroad, W. R. Lange. 1998. Current management of infectious complications in the injecting drug user. J. Substance Abuse Treatment 15 95-106.
17. Cooper, J. R. 1989. Methadone treatment and acquired immunodeficiency syndrome. J. Amer. Medical Assoc. 262 1664-1668.
18. Des Jarlais, D. C., S. R. Friedman, J. L. Sotheran, J. Wenston, M. Marmor, S. R. Yancovitz, B. Frank, S. Beatrice, D. Mildvan. 1994. Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. J. Amer. Medical Assoc. 271 121-127.
19. Edwards, D. M., R. M. Shachter, D. K. Owens. 1998. Analysis of therapeutic HIV vaccines. Interfaces 28 144-167.
20. French, M. T., L. J. Dunlap, G. A. Zarkin, K. A. McGeary, A. T. McLellan. 1997. A structured instrument for estimating the economic cost of drug abuse treatment. The drug abuse treatment cost analysis program (DATCAP). J. Substance Abuse Treatment 14 445-455.
21. Gable, C. B., J. C. Tierce, D. Simison, D. Ward, K. Motte. 1996. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. J. AIDS 12 413-420.
22. Gerstein, D. R., R. A. Johnson, H. Harwood, D. Fountain, N. Suter, K. Malloy. 1994. Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA). California Department of Drug and Alcohol Programs, Sacramento, CA.
23. Gleghorn, A. A., T. S. Jones, M. C. Doherty, D. D. Celentano, D. Vlahov. 1995. Acquisition and use of needles and syringes by injecting drug users in Baltimore, MD. J. AIDS 10 97-103.
24. Gold, M. R., J. E. Siegel, L. B. Russell, M. C. Weinstein. 1996. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York.
25. Hahn, R. A., I. M. Onorato, T. S. Jones, J. Dougherty. 1989. Prevalence of HIV infection among intravenous drug users in the United States. J. Amer. Medical Assoc. 261 2677-2684.
26. Harwood, J. J., R. L. Hubbard, J. J. Collins, J. V. Rachal. 1995. A cost-benefit analysis of drug abuse treatment. Res. Law and Policy Stud. 3 191-214.
27. Hethcote, H. W. 1976. Qualitative analyses of communicable disease models. Math. Biosci. 28 335-356.
28. _, J. A. Yorke 1984. Gonorrhea transmission dynamics and control. Lect. Notes Biomath. 56.
29. Holtgrave, D. R., S. D. Pinkerton. 1997. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J. AIDS 16 54-62.
30. Hubbard, R. L., M. E. Marsden, J. V. Rachal, H. J. Harwood, E. R. Cavanaugh, H. M. Ginsburg. 1989. Drug Abuse Treatment: A National Study of Effectiveness. University of North Carolina Press, Chapel Hill, NC.
31. Joe, G. W., D. D. Simpson. 1995. HIV risks, gender, and cocaine use among opiate users. Drug Alcohol Depend. 37 23-28.
32. Kahn, J. G. 1993. Are NEPs cost-effective in prevention of HIV infection? P. Lurie, A. L. Reingold, eds. The Public Health Impact of Needle Exchange Programs in the United States and Abroad. Institute for Health Policy Studies, University of California, San Francisco, CA. 475-509.
33. _, A. E. Washington, J. A. Showstack, M. Berlin, K. Phillips. 1992. Updated Estimates of the Impact and Cost of HIV Prevention in Injection Drug Users. Report Prepared for Centers for Disease Control. Institute for Health Policy Studies, University of California, San Francisco, CA.
34. Kaplan, E. H. 1995. Economic analysis of needle exchange. AIDS 9 1113-1119.
35. _, P R. Abramson. 1989. So what if the program ain't perfect? A mathematical model of AIDS education. Evaluation Rev. 13 107-122.
36. _, R. Heimer. 1992. A model-based estimate of HIV infectivity via needle sharing. J. AIDS 5 1116-1118.
37. _, Y. S. Lee. 1990. How bad can it get? Bounding worst case endemic hetergeneous mixing models of HIV/AIDS. Math. Biosci. 99 157-180.
38. Karon, J. M., P. S. Rosenberg, G. McQuillan, M. Khare, M. Gwinn, L. R. Petersen. 1996. Prevalence of HIV infection in the United States, 1984 to 1992. 1996. J. Amer. Medical Assoc. 276 126-131.
39. Koblin, B. A., J. McCusker, B. F. Lewis, J. L. Sullivan, 1990. Racial/ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study. Amer. J. Epidemiology 132 837-846.
40. Kretzschmar, M., L. G. Wiessing. 1998. Modeling the spread of HIV in social networks of injecting drug users. AIDS 12 801-811.
41. Maidlow, S. T., H. Berman. 1972. The economics of heroin treatment. Amer. J. Pub. Health 62 1397-1406.
42. Martin, G. S., G. Serpelloni, U. Galvan, A. Rizzetto, M. Gomma, S. Morgante, G. Rezza. 1990. Behavioural change in injecting drug users: Evaluation of an HIV/AIDS education programme. AIDS Care 2 275-279.
43. McAuliffe, W. E. 1990. Health care policy issues in the drug abuser treatment field. J. Health Political Policy Law 15 357-385.
44. McNaghten, A. D. 1998. The effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
45. Meandzija, B., P. G. O'Connor, B. Fitzgerald, B. J. Rounsaville, T. R. Kosten. 1994. HIV infection and cocaine use in methadone maintained and untreated injection drug users. Drug Alcohol Depend. 36 109-113.
46. Metzger, D. S., H. Navaline, G. E. Woody. 1998. Drug abuse treatment as AIDS prevention. Publ. Health Reports 113 (Supplement 1) 97-106.
47. _, G. E Woody, A. T. McLellan, C. P. O'Brien, P. Druley, H. Navaline, D. DePhilippis, P. Stolley, E. Abrutyn. 1993. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. J. AIDS 6 1049-1056.
48. Moore, R. D., J. Hidalgo, J. C. Bareta, R. E. Chaisson. 1994. Zidovudine therapy and health resource utilization in AIDS. J. AIDS 7 349-354.
49. Morris, M., M. Kretzschmar. 1995. Concurrent partnerships and transmission dynamics in networks. Soc. Networks 1 299-318.
50. Moss, A. R., K. Vranizan, R. Gorter, P. Bacchetti, J. Watters, D. Osmond. 1994. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 8 223-231.
51. Neaigus, A., S. R. Friedman, B. Jose, M. F. Goldstein, R. Curtis, G. Ildefonso, D. C. Des Jarlais. 1996. High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors. J. Acquir. Immune. Defic. Syndr. 11 499-509.
52. Owens, D. K. 1998. Interpretation of cost-effectiveness analyses [Editorial]. J. Gen. Internal Medicine 13 716-717.
53. _, M. L. Brandeau, C. H. Sox. 1998. Effects of relapse to high-risk behavior on the costs and benefits of a voluntary program to screen women for HIV. Interfaces 28 52-74.
54. _, A. M. Cardinalli, R. F. Nease, Jr. 1997. Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Quality of Life Res. 6 77-86.
55. _, R. F. Nease, Jr., R A. Harris. 1996. Cost-effectiveness of HIV screening in acute-care settings. Arch. Intern. Medicine 156 394-404.
56. Rettig, R. A., A. Yarmolinski. 1995. Federal Regulation of Methadone Treatment. National Academy Press, Washington, DC.
57. Scanlon, J. C. 1976. Proceedings: Cost savings/benefit analysis of drug abuse treatment. Amer. J. Drug Alcohol Abuse 3 95-101.
58. Schoenbaum, E. E., D. Hartel, P. A. Selwyn, R. S. Klein, K. Davenny, M. Rogers, C. Feiner, G. Friedland. 1989. Risk factors for human immunodeficiency virus infection in intravenous drug users. New England J. Med. 321 874-879.
59. Siegel, J. E., M. C. Weinstein, H. V. Fineberg. 1991. Bleach programs for preventing AIDS among IV drug users: Modeling the impact of HIV prevalence. Amer. J. Publ. Health 81 1273-1279.
60. Spencer, B. D. 1989. On the accuracy of estimates of numbers of intravenous drug users. C. F. Turner, H. G. Miller, L. E. Moses, eds. AIDS: Sexual Behavior and Intravenous Drug Use. National Academy Press, Washington, DC.
61. Suh, T., W. Mandell, C. Latkin, J. Kim. 1997. Social network characteristics and injecting HIV-risk behaviors among street injection drug users. Drug Alcohol Depend. 47 137-143.
62. Swarns, R. L. 1998. Mayor wants to abolish use of Methadone. New York Times, July 21, 1.
63. Tsevat, J., J. G. Solzan, K. M. Kuntz, J. Ragland, J. S. Currier, R L. Sell, M. C. Weinstein. 1996. Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Medical Care 34 44-57.
64. U.S. Bureau of Labor Statistics. 1998. Consumer Price Index. U.S. Government Printing Office, Washington, D.C.
65. U.S. Bureau of the Census. 1997. Statistical Abstract of the United States. U.S. Government Printing Office, Washington, D.C.
66. U.S. General Accounting Office. 1990a. The Effectiveness of Drug Abuse Treatment Implications for Controlling AIDS. U.S. Government Printing Office, Washington, D.C.
67. U.S. General Accounting Office. 1990b. Methadone Maintenance. Some Treatment Programs Are Not Effective; Greater Federal Oversight Needed. U.S. Government Printing Office, Washington, D.C.
68. U.S. Substance Abuse and Mental Health Services Administration (SAMHSA). 1992. Highlights from the 1991 National Drug and Alcoholism Treatment Unit Survey. Substance Abuse and Mental Health Services Administration, Rockville, MD.
69. von Limbeek, J., L. Wouters, C. D. Kaplan, P. J. Geerlings, V. von Alem. 1992. Prevalence of psychopathology in drug-addicted Dutch. J. Substance Abuse Treatment 9 43-52.
70. Watters, J. K. 1994. Trends in risk behavior and HIV seroprevalence in heterosexual injection drug users in San Francisco, 1986-1992. J. AIDS 7 1276-1281.
71. Watts, D. J. 1999. Networks, dynamics, and the small-world phenomenon. Amer. J. Soc. 105 493-527.
72. _, S. H. Strogatz. 1998. Collective dynamics of 'small-world' networks. Nature 393 440-442.
73. Zaric, G. S., P. G. Barnett, M. L. Brandeau. 2000. HIV transmission and the cost effectiveness of Methadone maintenance. Amer. J. Publ. Health 90 1100-1111.
74. _, M. L. Brandeau, A. M. Bayoumi, D. K. Owens. 1998. The effects of protease inhibitors on the spread of HIV and the development of drug-resistant HIV strains: A simulation study. Simulation 71 262-275.